2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Proton Pump

Proton Pump

Proton Pump

Related Products

PDF 0.87 MB

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Proton Pump Related Products (101):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-117025A
    Manzamine A hydrochloride
    		Inhibitor 99.66%
    Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1.
    Manzamine A hydrochloride
  • HY-W003467
    Rabeprazole Sulfide
    		Inhibitor 98.09%
    Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment.
    Rabeprazole Sulfide
  • HY-118283
    5-Hydroxylansoprazole
    		Inhibitor ≥99.0%
    5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases.
    5-Hydroxylansoprazole
  • HY-100560S
    Abscisic acid-d6
    		Inhibitor ≥98.0%
    Abscisic acid-d6 is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].
    Abscisic acid-d<sub>6</sub>
  • HY-B0656S
    Rabeprazole-d4
    		Inhibitor
    Rabeprazole-d4 is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
    Rabeprazole-d<sub>4</sub>
  • HY-W008614
    Lansoprazole sulfone
    		Inhibitor 99.52%
    Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H+, K+-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease.
    Lansoprazole sulfone
  • HY-B0656AS
    Rabeprazole-d4 sodium
    		Inhibitor 98.61%
    Rabeprazole-d4 (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
    Rabeprazole-d<sub>4</sub> sodium
  • HY-13662S
    Lansoprazole-d4
    		Inhibitor 99.82%
    Lansoprazole-d4 is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid[1].
    Lansoprazole-d<sub>4</sub>
  • HY-19223
    Pumaprazole
    		Antagonist 99.90%
    Pumaprazole is a reversible proton pump antagonist.
    Pumaprazole
  • HY-13662BS
    (R)-Lansoprazole-d4
    		Inhibitor 99.13%
    (R)-Lansoprazole-d4 is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
    (R)-Lansoprazole-d<sub>4</sub>
  • HY-N7031
    (±)​-​Vasicine
    		Inhibitor 99.92%
    (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H+-K+-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect.
    (±)​-​Vasicine
  • HY-13100
    PF 03716556
    		Antagonist 99.69%
    PF 03716556 is a potent, selective, competitive and reversible acid pump (H+,K+-ATPase) antagonist with pIC50s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H+,K+-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research.
    PF 03716556
  • HY-17021B
    Esomeprazole potassium salt
    		Inhibitor
    Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole potassium salt
  • HY-B0656
    Rabeprazole
    		Inhibitor 98.61%
    Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.
    Rabeprazole
  • HY-109546
    Omeprazole magnesium
    		Inhibitor
    Omeprazole magnesium is an orally active proton pump inhibitor (PPI) and can suppress gastric acid. Omeprazole magnesium can be used for acid reflux-related symptoms and frequent heartburn research.
    Omeprazole magnesium
  • HY-17021C
    Esomeprazole hemistrontium
    		Inhibitor
    Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research.
    Esomeprazole hemistrontium
  • HY-121851
    Revaprazan
    		Inhibitor
    Revaprazan (SB 641257) is a reversible proton pump inhibitor with significant anti-inflammatory effects. Revaprazan can be used for chronic gastric inflammation research.
    Revaprazan
  • HY-100007A
    Vonoprazan hydrochloride
    		Inhibitor
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori.
    Vonoprazan hydrochloride
  • HY-17507CS
    (R)-(+)-Pantoprazole-d6
    (R)-(+)-Pantoprazole-d6 is deuterium labeled (R)-(+)-Pantoprazole.
    (R)-(+)-Pantoprazole-d<sub>6</sub>
  • HY-17507S
    Pantoprazole-d6
    		Inhibitor
    Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
    Pantoprazole-d<sub>6</sub>